BLOG

Two drug candidates show promise against COVID-19 in organoid system

An Australian-based biotech company has announced positive, dose-dependent reductions against SARS-CoV-2 infection, the virus that causes COVID-19, following treatment with two anti-infective drug candidates, RECCE® 327 and RECCE® 529 (R327 and R529). Recce Pharmaceuticals, which developed the candidates, says it will be advancing the compounds to in vivo studies in ferrets in a US study.